Disc Medicine (IRON) Cash & Equivalents (2020 - 2026)

Disc Medicine (IRON) has reported Cash & Equivalents for 7 consecutive years, with $98.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents fell 22.51% year-over-year to $98.7 million; the TTM figure through Jun 2026 stood at $98.7 million (down 22.51% YoY), while the FY2025 annual figure was $91.1 million, down 52.64% from the prior year.
• Cash & Equivalents grew to $98.7 million in Q2 2026 per IRON's latest filing, from $88.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $377.6 million in Q2 2023 and bottomed at $88.9 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $197.0 million across 5 years, with a median of $166.5 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Equivalents jumped 264.21% — and 2025, when it plunged 64.19%.
• Disc Medicine's Cash & Equivalents stood at $194.6 million in 2022, then jumped by 85.18% to $360.4 million in 2023, then sank by 46.6% to $192.4 million in 2024, then plunged by 52.64% to $91.1 million in 2025, then gained by 8.26% to $98.7 million in 2026.
• Business Quant data shows IRON's Cash & Equivalents at $98.7 million in Q2 2026, $88.9 million in Q1 2026, and $91.1 million in Q4 2025.